LONDON, ONTARIO – January 28, 2021 – Sernova Corp. (TSX-V: SVA)(OTCQB: SEOVF)(FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, announced today that it has entered into multiple research collaboration agreements with global pharmaceutical companies.

Sernova is deploying its in-house cell therapy expertise and patent-protected Cell Pouch technologies in combination with proprietary therapeutic cell assets designated by the pharmaceutical collaborators. Further details of these agreements will be kept confidential for strategic reasons. The collaborators have requested anonymity.

Read More